慢性乙型肝炎联合治疗的现状和进展

Current status and advances of combination therapy for chronic hepatitis

慢性乙型肝炎（CHB）仍是一种全球性公共卫生疾病,可发展为失代偿性肝硬化和肝细胞癌.目前,没有单一的可用药物可以诱导强烈的HBV DNA抑制和高比例的HBeAg和HBsAg清除.因此,越来越多的研究开始寻求一些联合治疗方案,希望可以在有限的治疗过程后实现持续的病毒抑制和HBsAg阴转,实现临床治愈.该文就目前CHB单药治疗的缺陷、联合治疗主要方案的现状及进展进行概述.

Chronic hepatitis B （CHB） is still a global public health problem, resulting in the high risk of decompensated cirrhosis and hepatocellular carcinoma.At present, there are no single available medications that can induce both potent HBV DNA suppression, and high rates of HBeAg and HBsAg clearance.Therefore, there is great interest in developing combination therapies for patients with chronic HBV infection, which can achieve sustained viral suppression and HBsAg negative inversion after a finite course of treatment leading to clinical cure.This article reviews the current status and advances of combination therapy for CHB.